Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.

ABSTRACT:

Background

Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched.

Methods

In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO₂/FiO₂ < 200 receiving tocilizumab plus usual care versus usual care alone. Tocilizumab was administered at the time point that PaO₂/FiO₂ < 200 was observed. The primary outcome was 28-day mortality. Secondary outcomes included time to discharge, change in PaO₂/FiO2 at day 5 and change in WHO progression scale at day 10.

Findings

Overall, 114 patients were included in the analysis (tocilizumab plus usual care: 56, usual care: 58). Allocation to usual care was associated with

SUBMITTER: Karampitsakos T 

PROVIDER: S-EPMC8692825 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature